ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Research Report 2026
Published Date: 2026-03-05
|
Report Code: QYRE-Auto-275
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global PARP Poly ADP Ribose Polymerase Inhibitor Market Size Manufacturers Supply Chain Sales Channel and Clients 2021 2027
BUY CHAPTERS

Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Research Report 2026

Code: QYRE-Auto-275
Report
2026-03-05
Pages:110
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Astrazeneca plc
Tesaro
Merck
Clovis Oncology
Pfizer Inc
GSK
ZAI LAB
HENGRUI Medical

PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size

The global PARP (Poly ADP-Ribose Polymerase) Inhibitor market was valued at US$ 5995 million in 2025 and is anticipated to reach US$ 10800 million by 2032, at a CAGR of 8.9% from 2026 to 2032.

PARP (Poly ADP-Ribose Polymerase) Inhibitor Market

PARP (Poly ADP-Ribose Polymerase) Inhibitor Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on PARP (Poly ADP-Ribose Polymerase) Inhibitor competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP). They are developed for multiple indications; the most important is the treatment of cancer. Several forms of cancer are more dependent on PARP than regular cells, making PARP an attractive target for cancer therapy. PARP inhibitors appear to improve progression-free survival in women with recurrent platinum-sensitive ovarian cancer, as evidenced mainly by olaparib added to conventional treatment. In our report, we only study four approved PARPi (Lynparza, Zejula, Rubraca and Talzenna). One unit is one tablet or one capsule.
Market Driver: The increasing prevalence of cancer, particularly ovarian, breast, and prostate cancers, is a major driver of the PARP inhibitors market. As targeted therapies become more popular for cancer treatment, PARP inhibitors, which work by blocking the repair of DNA damage in cancer cells, have shown promising results in clinical trials, especially for patients with specific genetic mutations such as BRCA1 and BRCA2. The growing recognition of the effectiveness of PARP inhibitors in both monotherapy and combination treatments is driving demand, as these therapies offer personalized treatment options with fewer side effects compared to traditional chemotherapy. Ongoing research and the expansion of indications for PARP inhibitors in other cancers also contribute to market growth.
Market Challenge: One of the key challenges for the PARP inhibitors market is the high cost of these therapies, which limits patient access and increases the financial burden on healthcare systems. Despite their effectiveness, the prices of PARP inhibitors are often prohibitively expensive, particularly for long-term use. Additionally, not all cancer patients benefit from PARP inhibition, and there is a risk of resistance developing over time, which can reduce the long-term efficacy of the drugs. Regulatory hurdles and the need for further clinical evidence to support broader indications also pose challenges to market expansion. As the market evolves, ensuring access and affordability while continuing to innovate will be critical to overcoming these barriers.
Global PARP (Poly ADP-Ribose Polymerase) Inhibitor key players include AstraZeneca, Tesaro, Merck & Co, etc. Global top three manufacturers hold a share about 90%. North America is the largest market, with a share about 70%, followed by Europe and Emerging Country, both have a share about 25 percent. In terms of product, Lynparza is the largest segment, with a share over 65%. And in terms of application, the largest application is Ovarian Cancer, followed by Breast Cancer.
This report delivers a comprehensive overview of the global PARP (Poly ADP-Ribose Polymerase) Inhibitor market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding PARP (Poly ADP-Ribose Polymerase) Inhibitor. The PARP (Poly ADP-Ribose Polymerase) Inhibitor market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global PARP (Poly ADP-Ribose Polymerase) Inhibitor market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist PARP (Poly ADP-Ribose Polymerase) Inhibitor manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Report

Report Metric Details
Report Name PARP (Poly ADP-Ribose Polymerase) Inhibitor Market
Accounted market size in 2025 US$ 5995 million
Forecasted market size in 2032 US$ 10800 million
CAGR 8.9%
Base Year 2025
Forecasted years 2026 - 2032
Segment by Type
  • Lynparza
  • Zejula
  • Rubraca
  • Talzenna
  • Other
by Application
  • Ovarian Cancer
  • Breast Cancer
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company AstraZeneca, Tesaro, Merck & Co, Clovis Oncology, Pfizer, GSK, Zai Lab, Hengrui Medical
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Provides a detailed analysis of the competitive landscape for PARP (Poly ADP-Ribose Polymerase) Inhibitor manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
  • Chapter 3: Examines PARP (Poly ADP-Ribose Polymerase) Inhibitor sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
  • Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
  • Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
  • Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
  • Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
  • Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

How fast is PARP (Poly ADP-Ribose Polymerase) Inhibitor Market growing?

Ans: The PARP (Poly ADP-Ribose Polymerase) Inhibitor Market witnessing a CAGR of 8.9% during the forecast period 2026-2032.

What is the PARP (Poly ADP-Ribose Polymerase) Inhibitor Market size in 2032?

Ans: The PARP (Poly ADP-Ribose Polymerase) Inhibitor Market size in 2032 will be US$ 10800 million.

What is the market share of major companies in PARP (Poly ADP-Ribose Polymerase) Inhibitor Market?

Ans: Global top three manufacturers hold a share about 90%.

What is the PARP (Poly ADP-Ribose Polymerase) Inhibitor Market share by region?

Ans: North America is the largest market, with a share about 70%, followed by Europe and Emerging Country, both have a share about 25 percent.

What is the PARP (Poly ADP-Ribose Polymerase) Inhibitor Market share by type?

Ans: In terms of product, Lynparza is the largest segment, with a share over 65%.

Who are the main players in the PARP (Poly ADP-Ribose Polymerase) Inhibitor Market report?

Ans: The main players in the PARP (Poly ADP-Ribose Polymerase) Inhibitor Market are AstraZeneca, Tesaro, Merck & Co, Clovis Oncology, Pfizer, GSK, Zai Lab, Hengrui Medical

What are the Application segmentation covered in the PARP (Poly ADP-Ribose Polymerase) Inhibitor Market report?

Ans: The Applications covered in the PARP (Poly ADP-Ribose Polymerase) Inhibitor Market report are Ovarian Cancer, Breast Cancer, Other

What are the Type segmentation covered in the PARP (Poly ADP-Ribose Polymerase) Inhibitor Market report?

Ans: The Types covered in the PARP (Poly ADP-Ribose Polymerase) Inhibitor Market report are Lynparza, Zejula, Rubraca, Talzenna, Other

1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Overview
1.1 Product Definition
1.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor by Type
1.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Value by Type: 2025 vs 2032
1.2.2 Lynparza
1.2.3 Zejula
1.2.4 Rubraca
1.2.5 Talzenna
1.2.6 Other
1.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor by Application
1.3.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Value by Application: 2025 vs 2032
1.3.2 Ovarian Cancer
1.3.3 Breast Cancer
1.3.4 Other
1.4 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size Estimates and Forecasts
1.4.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue 2021–2032
1.4.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales 2021–2032
1.4.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Competition by Manufacturers
2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Manufacturers (2021–2026)
2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Manufacturers (2021–2026)
2.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of PARP (Poly ADP-Ribose Polymerase) Inhibitor, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of PARP (Poly ADP-Ribose Polymerase) Inhibitor, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of PARP (Poly ADP-Ribose Polymerase) Inhibitor, Product Types and Applications
2.7 Global Key Manufacturers of PARP (Poly ADP-Ribose Polymerase) Inhibitor, Date of Entry into the Industry
2.8 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Competitive Situation and Trends
2.8.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Players Market Share by Revenue
2.8.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Scenario by Region
3.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region: 2021–2032
3.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region: 2021–2026
3.2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region: 2027–2032
3.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region: 2021–2032
3.3.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region: 2021–2026
3.3.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region: 2027–2032
3.4 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Facts & Figures by Country
3.4.1 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2021–2032)
3.4.3 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2021–2032)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Facts & Figures by Country
3.5.1 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2021–2032)
3.5.3 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Facts & Figures by Region
3.6.1 Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region (2021–2032)
3.6.3 Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Facts & Figures by Country
3.7.1 Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2021–2032)
3.7.3 Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Facts & Figures by Country
3.8.1 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2021–2032)
3.8.3 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2021–2032)
4.1.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2021–2026)
4.1.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2027–2032)
4.1.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2021–2032)
4.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2021–2032)
4.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2021–2026)
4.2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2027–2032)
4.2.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Type (2021–2032)
4.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Type (2021–2032)
5 Segment by Application
5.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2021–2032)
5.1.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2021–2026)
5.1.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2027–2032)
5.1.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2021–2032)
5.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application (2021–2032)
5.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application (2021–2026)
5.2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application (2027–2032)
5.2.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Application (2021–2032)
5.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Application (2021–2032)
6 Key Companies Profiled
6.1 AstraZeneca
6.1.1 AstraZeneca Company Information
6.1.2 AstraZeneca Description and Business Overview
6.1.3 AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
6.1.5 AstraZeneca Recent Developments/Updates
6.2 Tesaro
6.2.1 Tesaro Company Information
6.2.2 Tesaro Description and Business Overview
6.2.3 Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
6.2.5 Tesaro Recent Developments/Updates
6.3 Merck & Co
6.3.1 Merck & Co Company Information
6.3.2 Merck & Co Description and Business Overview
6.3.3 Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
6.3.5 Merck & Co Recent Developments/Updates
6.4 Clovis Oncology
6.4.1 Clovis Oncology Company Information
6.4.2 Clovis Oncology Description and Business Overview
6.4.3 Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
6.4.5 Clovis Oncology Recent Developments/Updates
6.5 Pfizer
6.5.1 Pfizer Company Information
6.5.2 Pfizer Description and Business Overview
6.5.3 Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
6.5.5 Pfizer Recent Developments/Updates
6.6 GSK
6.6.1 GSK Company Information
6.6.2 GSK Description and Business Overview
6.6.3 GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
6.6.5 GSK Recent Developments/Updates
6.7 Zai Lab
6.7.1 Zai Lab Company Information
6.7.2 Zai Lab Description and Business Overview
6.7.3 Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
6.7.5 Zai Lab Recent Developments/Updates
6.8 Hengrui Medical
6.8.1 Hengrui Medical Company Information
6.8.2 Hengrui Medical Description and Business Overview
6.8.3 Hengrui Medical PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Hengrui Medical PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
6.8.5 Hengrui Medical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Chain Analysis
7.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Production Mode & Process Analysis
7.4 PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Marketing
7.4.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Channels
7.4.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Distributors
7.5 PARP (Poly ADP-Ribose Polymerase) Inhibitor Customer Analysis
8 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Dynamics
8.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Trends
8.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Drivers
8.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Challenges
8.4 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Astrazeneca plc
Tesaro
Merck
Clovis Oncology
Pfizer Inc
GSK
ZAI LAB
HENGRUI Medical
List of Tables
 Table 1. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Value by Type (US$ Million), 2025 vs 2032
 Table 2. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Value by Application (US$ Million), 2025 vs 2032
 Table 3. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Competitive Situation by Manufacturers in 2025
 Table 4. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units) of Key Manufacturers (2021–2026)
 Table 5. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Manufacturers (2021–2026)
 Table 6. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (US$ Million) by Manufacturers (2021–2026)
 Table 7. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Manufacturers (2021–2026)
 Table 8. Global Market PARP (Poly ADP-Ribose Polymerase) Inhibitor Average Price (USD/Unit) of Key Manufacturers (2021–2026)
 Table 9. Global Key Players of PARP (Poly ADP-Ribose Polymerase) Inhibitor, Industry Ranking, 2023 vs 2024 vs 2025
 Table 10. Global Key Manufacturers of PARP (Poly ADP-Ribose Polymerase) Inhibitor, Manufacturing Sites and Headquarters
 Table 11. Global Key Manufacturers of PARP (Poly ADP-Ribose Polymerase) Inhibitor, Product Types and Applications
 Table 12. Global Key Manufacturers of PARP (Poly ADP-Ribose Polymerase) Inhibitor, Date of Entry into the Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Companies by Tier (Tier 1, Tier 2, Tier 3), based on PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue, 2025
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 17. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region (K Units), 2021–2026
 Table 18. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Region (2021–2026)
 Table 19. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region (K Units), 2027–2032
 Table 20. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Region (2027–2032)
 Table 21. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region (US$ Million), 2021–2026
 Table 22. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Region (2021–2026)
 Table 23. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region (US$ Million), 2027–2032
 Table 24. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Region (2027–2032)
 Table 25. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 26. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (K Units), 2021–2026
 Table 27. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (K Units), 2027–2032
 Table 28. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (US$ Million), 2021–2026
 Table 29. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (US$ Million), 2027–2032
 Table 30. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 31. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (K Units), 2021–2026
 Table 32. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (K Units), 2027–2032
 Table 33. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (US$ Million), 2021–2026
 Table 34. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (US$ Million), 2027–2032
 Table 35. Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
 Table 36. Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region (K Units), 2021–2026
 Table 37. Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region (K Units), 2027–2032
 Table 38. Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region (US$ Million), 2021–2026
 Table 39. Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region (US$ Million), 2027–2032
 Table 40. Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 41. Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (K Units), 2021–2026
 Table 42. Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (K Units), 2027–2032
 Table 43. Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (US$ Million), 2021–2026
 Table 44. Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (US$ Million), 2027–2032
 Table 45. Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 46. Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (K Units), 2021–2026
 Table 47. Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (K Units), 2027–2032
 Table 48. Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (US$ Million), 2021–2026
 Table 49. Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (US$ Million), 2027–2032
 Table 50. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units) by Type (2021–2026)
 Table 51. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units) by Type (2027–2032)
 Table 52. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2021–2026)
 Table 53. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2027–2032)
 Table 54. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (US$ Million) by Type (2021–2026)
 Table 55. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (US$ Million) by Type (2027–2032)
 Table 56. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Type (2021–2026)
 Table 57. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Type (2027–2032)
 Table 58. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price (USD/Unit) by Type (2021–2026)
 Table 59. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price (USD/Unit) by Type (2027–2032)
 Table 60. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units) by Application (2021–2026)
 Table 61. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units) by Application (2027–2032)
 Table 62. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2021–2026)
 Table 63. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2027–2032)
 Table 64. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (US$ Million) by Application (2021–2026)
 Table 65. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (US$ Million) by Application (2027–2032)
 Table 66. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Application (2021–2026)
 Table 67. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Application (2027–2032)
 Table 68. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price (USD/Unit) by Application (2021–2026)
 Table 69. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price (USD/Unit) by Application (2027–2032)
 Table 70. AstraZeneca Company Information
 Table 71. AstraZeneca Description and Business Overview
 Table 72. AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
 Table 73. AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Product
 Table 74. AstraZeneca Recent Developments/Updates
 Table 75. Tesaro Company Information
 Table 76. Tesaro Description and Business Overview
 Table 77. Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
 Table 78. Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Product
 Table 79. Tesaro Recent Developments/Updates
 Table 80. Merck & Co Company Information
 Table 81. Merck & Co Description and Business Overview
 Table 82. Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
 Table 83. Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Product
 Table 84. Merck & Co Recent Developments/Updates
 Table 85. Clovis Oncology Company Information
 Table 86. Clovis Oncology Description and Business Overview
 Table 87. Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
 Table 88. Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Product
 Table 89. Clovis Oncology Recent Developments/Updates
 Table 90. Pfizer Company Information
 Table 91. Pfizer Description and Business Overview
 Table 92. Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
 Table 93. Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Product
 Table 94. Pfizer Recent Developments/Updates
 Table 95. GSK Company Information
 Table 96. GSK Description and Business Overview
 Table 97. GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
 Table 98. GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Product
 Table 99. GSK Recent Developments/Updates
 Table 100. Zai Lab Company Information
 Table 101. Zai Lab Description and Business Overview
 Table 102. Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
 Table 103. Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Product
 Table 104. Zai Lab Recent Developments/Updates
 Table 105. Hengrui Medical Company Information
 Table 106. Hengrui Medical Description and Business Overview
 Table 107. Hengrui Medical PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
 Table 108. Hengrui Medical PARP (Poly ADP-Ribose Polymerase) Inhibitor Product
 Table 109. Hengrui Medical Recent Developments/Updates
 Table 110. Key Raw Materials Lists
 Table 111. Raw Materials Key Suppliers Lists
 Table 112. PARP (Poly ADP-Ribose Polymerase) Inhibitor Distributors List
 Table 113. PARP (Poly ADP-Ribose Polymerase) Inhibitor Customers List
 Table 114. PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Trends
 Table 115. PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Drivers
 Table 116. PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Challenges
 Table 117. PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Restraints
 Table 118. Research Programs/Design for This Report
 Table 119. Key Data Information from Secondary Sources
 Table 120. Key Data Information from Primary Sources
 Table 121. Authors List of This Report


List of Figures
 Figure 1. Product Picture of PARP (Poly ADP-Ribose Polymerase) Inhibitor
 Figure 2. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Value by Type (US$ Million), 2021–2032
 Figure 3. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share by Type: 2025 & 2032
 Figure 4. Lynparza Product Picture
 Figure 5. Zejula Product Picture
 Figure 6. Rubraca Product Picture
 Figure 7. Talzenna Product Picture
 Figure 8. Other Product Picture
 Figure 9. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Value by Application (US$ Million), 2021–2032
 Figure 10. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share by Application: 2025 & 2032
 Figure 11. Ovarian Cancer
 Figure 12. Breast Cancer
 Figure 13. Other
 Figure 14. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue, (US$ Million), 2021 vs 2025 vs 2032
 Figure 15. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size (US$ Million), 2021–2032
 Figure 16. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), 2021–2032
 Figure 17. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Average Price (USD/Unit), 2021–2032
 Figure 18. PARP (Poly ADP-Ribose Polymerase) Inhibitor Report Years Considered
 Figure 19. PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Share by Manufacturers in 2025
 Figure 20. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Manufacturers in 2025
 Figure 21. Top 5 and Top 10 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Players: Market Share by Revenue in PARP (Poly ADP-Ribose Polymerase) Inhibitor in 2025
 Figure 22. PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
 Figure 23. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Figure 24. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Country (2021–2032)
 Figure 25. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Country (2021–2032)
 Figure 26. U.S. PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
 Figure 27. Canada PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
 Figure 28. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Country (2021–2032)
 Figure 29. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Country (2021–2032)
 Figure 30. Germany PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
 Figure 31. France PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
 Figure 32. U.K. PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
 Figure 33. Italy PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
 Figure 34. Russia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
 Figure 35. Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Region (2021–2032)
 Figure 36. Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Region (2021–2032)
 Figure 37. China PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
 Figure 38. Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
 Figure 39. South Korea PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
 Figure 40. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
 Figure 41. Australia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
 Figure 42. Taiwan PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
 Figure 43. Indonesia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
 Figure 44. Thailand PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
 Figure 45. Malaysia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
 Figure 46. Philippines PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
 Figure 47. Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Country (2021–2032)
 Figure 48. Latin America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Country (2021–2032)
 Figure 49. Mexico PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
 Figure 50. Brazil PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
 Figure 51. Argentina PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
 Figure 52. Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Country (2021–2032)
 Figure 53. Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Country (2021–2032)
 Figure 54. Turkey PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
 Figure 55. Saudi Arabia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
 Figure 56. UAE PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
 Figure 57. Global Sales Market Share of PARP (Poly ADP-Ribose Polymerase) Inhibitor by Type (2021–2032)
 Figure 58. Global Revenue Market Share of PARP (Poly ADP-Ribose Polymerase) Inhibitor by Type (2021–2032)
 Figure 59. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price (USD/Unit) by Type (2021–2032)
 Figure 60. Global Sales Market Share of PARP (Poly ADP-Ribose Polymerase) Inhibitor by Application (2021–2032)
 Figure 61. Global Revenue Market Share of PARP (Poly ADP-Ribose Polymerase) Inhibitor by Application (2021–2032)
 Figure 62. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price (USD/Unit) by Application (2021–2032)
 Figure 63. PARP (Poly ADP-Ribose Polymerase) Inhibitor Value Chain
 Figure 64. Channels of Distribution (Direct Vs Distribution)
 Figure 65. Bottom-up and Top-down Approaches for This Report
 Figure 66. Data Triangulation
 Figure 67. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SecuX Technology Inc

SIMILAR REPORTS

PARP Inhibitors for Cancer Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Prostate Cancer PARP Inhibitor Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Poly ADP Ribose Polymerase PARP Inhibitors Market Research Report 2024
Global Niraparib API Market Research Report 2024
DNA Repair PARP Inhibitor Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Enzyme Poly ADP Ribose Polymerase Inhibitor Market Insights Forecast to 2030
Global Ovarian Cancer Microtubule Inhibitors Market Research Report 2025
Global PARP Poly ADP ribose Polymerase Inhibitors Market Insights Forecast to 2030
Cancer Drug based on PARP Inhibitor Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Olaparib API Market Research Report 2024
Global PARP Inhibitors for Breast Cancer Market Research Report 2024
Global Niraparib Preparations Market Research Report 2024
Global Enzyme Poly ADP Ribose Polymerase PARP Inhibitor Market Insights Forecast to 2030
Global PARP Inhibitor Biomarkers Testing Product Market Research Report 2024
Global PARP Inhibitor Biomarkers Service Market Research Report 2024
Global PARP1 Antibody Market Research Report 2024
Global PD 1 and PDL 1 Inhibitors Market Research Report 2025
Pd 1 and Pd L1 Inhibitors Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global BRAF Inhibitors Market Research Report 2024
DNA Repair Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions